Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Secukinumab biosimilar - Mabpharm

Drug Profile

Secukinumab biosimilar - Mabpharm

Alternative Names: CMAB-015

Latest Information Update: 07 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mabpharm
  • Developer Mabpharm; Taizhou Mabtech Pharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics; Antihyperglycaemics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action IL17F protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Psoriasis
  • Preclinical Ankylosing spondylitis

Most Recent Events

  • 03 May 2024 Taizhou Mabtech Pharmaceutical plans a phase III trial for Plaque psoriasis (SC, Injection) in May 2024 (NCT06398652)
  • 03 Jun 2023 Taizhou Mabtech Pharmaceutical completes a phase-I trial in Psoriasis (In volunteers) in China (SC) (NCT05734482)
  • 28 Feb 2023 Mabpharm plans a clinical trial in Ankylosing spondylitis in China
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top